Tumor Duration of Response More Than Doubled: Durvalumab Combined with Olaparib in Phase III DUO-E Trial Meets Multiple Key Secondary Endpoints

Mar 19, 2024 07:47 CST Updated 07:47

AstraZeneca

Biopharmaceutical Manufacturer

March 18,AstraZenecaAnnouncement of the latest analysis results from the Phase III DUO-E trial shows that, compared with chemotherapy alone, patients receivingImfinzi(Durvalumab) in combination with platinum-based chemotherapy, followed by the use of Imfinzi in combinationLynparza(Olaparib) can improve multiple key secondary efficacy endpoints in patients, especially in those with advanced or recurrent endometrial cancer who have proficient mismatch repair (pMMR).

An exploratory post-hoc subgroup analysis assessed patients by mismatch repair (MMR) status.In pMMR patientsThe median duration of response (DoR) in the Imfinzi plus Lynparza group was more than double that of the control group (18.7 months vs 7.6 months). Compared with the control group, the combination therapy group reduced the risk of second progression or death (PFS2) by 32% (not reached vs 19.5 months, HR 0.68; 95% confidence interval [CI] 0.48-0.95).

Regardless of MMR status, Imfinzi followed by Imfinzi monotherapy after combination with chemotherapy (Imfinzi group) also demonstrated consistent benefits; in mismatch repair-deficient (dMMR) patients,The greatest benefit was observed in all secondary endpoints:Control GroupObjective Response Rate (ORR)At 40.5%,DoRFor 10.5 months,Imfinzi GroupORR was 71.4%, DoR not reached.

In the overall trial population, results from the Lynparza and Imfinzi groups showed an extended ORR and DoR, along with sustained improvements in secondary endpoints, including overall survival (OS), time to first subsequent treatment (TFST), PFS2, and time to second subsequent treatment (TSST).

AstraZeneca's Executive Vice President of Oncology R&D, Susan Galbraith, stated: "The DUO-E results demonstrate that adding Imfinzi to chemotherapy can lead to better outcomes for patients with advanced endometrial cancer. Furthermore, this offers new hope to patients with significant unmet needs (Normal Mismatch Repair Function"To achieve the best clinical benefit for patients, the addition of Lynparza further enhances the role of checkpoint inhibition in endometrial cancer."

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.

Exciting Preview

Offline Salon

↑ Long pressScan the code, Register for the Salon ↑

↑Long press to identify QR code / ScanRegistration is now open.↑